Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2946886 | 1.00 | L3MBTL1 (0.33) | L3MBTL1ELANE | |
| SCHEMBL13236739 | 1.00 | L3MBTL1 (0.33) | L3MBTL1ELANE | |
| SCHEMBL20787026 | 0.66 | ELANE (0.33) | ELANE | |
| SCHEMBL7564598 | 0.63 | ELANE (0.32) | L3MBTL1ELANE | |
| SCHEMBL9856833 | 0.63 | NFKB1 (0.49) | ELANE | |
| SCHEMBL2950670 | 0.62 | — | — | |
| SCHEMBL10505719 | 0.61 | ELANE (0.34) | ELANE | |
| SCHEMBL10505728 | 0.61 | ELANE (0.34) | ELANE | |
| SCHEMBL12858082 | 0.60 | ELANE (0.36) | ELANE | |
| SCHEMBL1150265 | 0.60 | ELANE (0.36) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759399-B2 | Pharmaceutical compositions | CRAWFORD HEALTHCARE HOLDINGS LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-7759399-B2 | Pharmaceutical compositions | CRAWFORD HEALTHCARE HOLDINGS LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-7759399-B2 | Pharmaceutical compositions | CRAWFORD HEALTHCARE HOLDINGS LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-20060252839-A1 | Pharmaceutical compositions | BIOGEM S.C.A.R.L. (IT) | 2006-11-09 | — | — | US | disclosed |
| EP-1487789-A2 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | Charterhouse Therapeutics Ltd. (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082813-A2 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS | CHARTERHOUSE THERAPEUTICS LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252839-A1 | Pharmaceutical compositions | ADK, SYMPK, CYP2J2 | L3MBTL1 4855/4885ELANE 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.